Motherhood Statements: Cardiovascular Effect of Liraglutide and Syphilis Screening

Subscribe on iTunes

This week, Amol and Rebecca discuss a recent study and an updated recommendation:

A multi-centre, randomized control trial (the LEADER trial) examined the cardiovascular effect of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue. Patients with type 2 diabetes and high cardiovascular risk were randomly assigned to receive either standard of care plus liraglutide or standard of care plus placebo. In the time-to-event analysis, the study found that over a median follow up of 3.8 years, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke was lower with liraglutide than with placebo. Rebecca and Amol compare the results of this trial to previous studies.

The United States Preventive Services Task Force (USPSTF) reviewed the evidence on syphilis and recommends that adult patients at higher risk for syphilis should be screened. This is based on evidence that screening for syphilis in high risk patients provides substantial benefit, treatment of early syphilis is highly effective and no direct evidence of harm has been found from screening. Amol and Rebecca discuss how to screen and treat syphilis, and why this infectious disease has been on the rise.

Rate us on iTune! Follow us on Twitter @roundstable

The Papers

1. Liraglutide:

2. Syphilis:

Good Stuff

1. Infant sleep training:

2. Surgeon tryouts:

Music Credits (Creative Commons)

In your Robotic Heart – Nicolai Heidlas

Drive – Nicolai Heidlas

Vintage Dream – Nicolai Heidlas

All tracks have been modified for the purposes of this podcast.

Leave a Comment